Pharmacotherapy for functional gastrointestinal disorders in children

Current Opinion in Pharmacology

Volumn 6, Issue 6, 2006, Pages 536-540

  Chitkara, Denesh K ^a   Di Lorenzo, Carlo ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; DOMPERIDONE; ELECTROLYTE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LACTULOSE; LAXATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROGOL 3350; METOCLOPRAMIDE; MONTELUKAST; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; CHILD; CLINICAL TRIAL; CONSTIPATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; FECES INCONTINENCE; GASTROESOPHAGEAL REFLUX; HUMAN; IRRITABLE COLON; MEDICATION ERROR; PRIORITY JOURNAL; REVIEW; SUICIDAL IDEATION; THERAPEUTIC ERROR; UNSPECIFIED SIDE EFFECT;

CHILD; CONSTIPATION; DYSPEPSIA; GASTROINTESTINAL DISEASES; HUMANS; IRRITABLE BOWEL SYNDROME;

EID: 33750511974     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.06.008     Document Type: Review

References (42)

1. Hyams J.S., Burke G., Davis P.M., Rzepski B., and Andrulonis P.A. Abdominal pain and irritable bowel syndrome in adolescents: a community-based study. J Pediatr 129 (1996) 220-226
2. De Giacomo C., Valdambrini V., Lizzoli F., Gissi A., Palestra M., Tinelli C., Zagari M., and Bazzoli F. A population-based survey on gastrointestinal tract symptoms and Helicobacter pylori infection in children and adolescents. Helicobacter 7 (2002) 356-363
3. Chitkara DK, Talley NJ, Weaver AL, Katusic SK, De Schepper H, Rucker MJ, Locke GR 3rd: Incidence of presentation of common functional gastrointestinal disorders in children from birth-5 years: a cohort study. Clin Gastroenterol Hepatol 2006, in press. A population-based, retrospective study showing that incidences of presentation of GERD, abdominal pain of unknown origin, and constipation are among the highest for pediatric disorders.
4. Van Ginkel R., Voskuijl W.P., Benninga M.A., Taminiau J.A., and Boeckxstaens G.E. Alterations in rectal sensitivity and motility in childhood irritable bowel syndrome. Gastroenterology 120 (2001) 31-38
5. Chitkara D.K., Bredenoord A.J., Cremonini F., Delgado-Aros S., Smoot R.L., El-Youssef M., Freese D., and Camilleri M. The role of pelvic floor dysfunction and slow colonic transit in adolescents with refractory constipation. Am J Gastroenterol 99 (2004) 1579-1584
6. Benninga M.A., Voskuijl W.P., Akkerhuis G.W., Taminiau J.A., and Buller H.A. Colonic transit times and behaviour profiles in children with defecation disorders. Arch Dis Child 89 (2004) 13-16
7. Loening-Baucke V., and Panshankar D. A randomized prospective comparison study of polyethylene glycol without eletrolytes and milk of magnesia for children with constipation and fecal soiling. Gastroenterology 128 (2005) A-168
8. Nurko S., Youssef N.N., Sabri M., Langseder A.L., Seese C., McRandal S., McGowan J., and Di Lorenzo C. Peg3350 in the treatment of children with chronic constipation. Results of a short term, multicenter, double blind, placebo controlled trial. Gastroenterology 128 (2005) A-168
9. Youssef N.N., Peters J.M., Henderson W., Shultz-Peters S., Lockhart D.K., and Di Lorenzo C. Dose response of PEG 3350 for the treatment of childhood fecal impaction. J Pediatr 141 (2002) 410-414
10. Pashankar D.S., Loening-Baucke V., and Bishop W.P. Safety of polyethylene glycol 3350 for the treatment of chronic constipation in children. Arch Pediatr Adolesc Med 157 (2003) 661-664
11. Pashankar D.S., Bishop W.P., and Loening-Baucke V. Long-term efficacy of polyethylene glycol 3350 for the treatment of chronic constipation in children with and without encopresis. Clin Pediatr (Phila) 42 (2003) 815-819
12. Voskuijl W., de Lorijn F., Verwijs W., Hogeman P., Heijmans J., Makel W., Taminiau J., and Benninga M. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial. Gut 53 (2004) 1590-1594
13. Michail S., Gendy E., Preud'Homme D., and Mezoff A. Polyethylene glycol for constipation in children younger than eighteen months old. J Pediatr Gastroenterol Nutr 39 (2004) 197-199
14. Loening-Baucke V., Krishna R., and Pashankar D.S. Polyethylene glycol 3350 without electrolytes for the treatment of functional constipation in infants and toddlers. J Pediatr Gastroenterol Nutr 39 (2004) 536-539
15. Narducci F., Bassotti G., Gaburri M., and Morelli A. Twenty four hour manometric recording of colonic motor activity in healthy man. Gut 28 (1987) 17-25
16. Hamid S.A., Di Lorenzo C., Reddy S.N., Flores A.F., and Hyman P.E. Bisacodyl and high-amplitude-propagating colonic contractions in children. J Pediatr Gastroenterol Nutr 27 (1998) 398-402
17. van den Berg M.M., Hogan M., Caniano D.A., Di Lorenzo C., Benninga M.A., and Mousa H.M. Colonic manometry as predictor of cecostomy success in children with defecation disorders. J Pediatr Surg 41 (2006) 730-736
18. Chitkara D.K., Camilleri M., Zinsmeister A.R., Burton D., El-Youssef M., Freese D., Walker L., and Stephens D. Gastric sensory and motor dysfunction in adolescents with functional dyspepsia. J Pediatr 146 (2005) 500-505
19. Chitkara D.K., Delgado-Aros S., Bredenoord A.J., Cremonini F., El-Youssef M., Freese D., and Camilleri M. Functional dyspepsia, upper gastrointestinal symptoms, and transit in children. J Pediatr 143 (2003) 609-613
20. Talley NJ, Lauritsen K: The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies. Gut 2002, 50(Suppl 4):iv36-iv41.
21. Veldhuyzen van Zanten S.J., Jones M.J., Verlinden M., and Talley N.J. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 96 (2001) 689-696
22. Degen L., Matzinger D., Merz M., Appel-Dingemanse S., Osborne S., Luchinger S., Bertold R., Maecke H., and Beglinger C. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 15 (2001) 1745-1751
23. Mertz H.P.D., Smith S., and Morgan V. Amitriptyline reduces visceral sensitization and limbic activation induced by stress in IBS and improves symptoms. Gastroenterology 122 (2002) A-310
24. Tack J., Piessevaux H., Coulie B., Caenepeel P., and Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 115 (1998) 1346-1352
25. Tack J. Functional dyspepsia: impaired fundic accommodation. Curr Treat Options Gastroenterol 3 (2000) 287-294
26. See M.C., Birnbaum A.H., Schechter C.B., Goldenberg M.M., and Benkov K.J. Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment. Dig Dis Sci 46 (2001) 985-992
27. Friesen C.A., Andre L., Garola R., Hodge C., and Roberts C. Activated duodenal mucosal eosinophils in children with dyspepsia: a pilot transmission electron microscopic study. J Pediatr Gastroenterol Nutr 35 (2002) 329-333
28. Friesen C.A., Kearns G.L., Andre L., Neustrom M., Roberts C.C., and Abdel-Rahman S.M. Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr 38 (2004) 343-351
29. Stutts J.T., Caines K.E., Dickens C.H., Lipani T.A., and Walker L.S. Diagnostic subgroups of functional gastrointestinal disorders in children with recurrent abdominal pain. J Pediatr Gastroenterol Nutr 31 (2000) S176
30. Di Lorenzo C., Colletti R.B., Lehmann H.P., Boyle J.T., Gerson W.T., Hyams J.S., Squires Jr. R.H., Walker L.S., and Kanda P.T. Chronic abdominal pain in children: a technical report of the american academy of pediatrics and the north american society for pediatric gastroenterology, hepatology and nutrition: AAP subcommittee and naspghan committee on chronic abdominal pain. J Pediatr Gastroenterol Nutr 40 (2005) 249-261. A systematic literature review of the diagnostic and therapeutic value of history, physical examination, diagnostic tests, and pharmacological and behavioral therapy in pain-predominant childhood functional GI disorders.
31. Huertas-Ceballos A, Macarthur C, Logan S: Pharmacological interventions for recurrent abdominal pain (RAP) in childhood. Cochrane Database Syst Rev 2002, (1):CD003017.
32. Weydert J.A., Ball T.M., and Davis M.F. Systematic review of treatments for recurrent abdominal pain. Pediatrics 111 (2003) e1-e11
33. Drossman D.A., Toner B.B., Whitehead W.E., Diamant N.E., Dalton C.B., Duncan S., Emmott S., Proffitt V., Akman D., Frusciante K., et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 125 (2003) 19-31
34. Campo J.V., Perel J., Lucas A., Bridge J., Ehmann M., Kalas C., Monk K., Axelson D., Birmaher B., Ryan N., et al. Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: an exploratory study. J Am Acad Child Adolesc Psychiatry 43 (2004) 1234-1242
35. Jick H., Kaye J.A., and Jick S.S. Antidepressants and the risk of suicidal behaviors. J Am Med Assoc 292 (2004) 338-343
36. Prather C.M., Camilleri M., Zinsmeister A.R., McKinzie S., and Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 118 (2000) 463-468
37. Khoshoo V., Armstead C., and Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 23 (2006) 191-196. A pediatric randomized study that selected patients based on Rome criteria. It suggested that addition of tegaserod to a laxative results in more pain relief in constipation-predominant irritable bowel syndrome.
38. Milne C.P. Pediatric research: coming of age in the new millennium. Am J Ther 6 (1999) 263-282
39. Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L: Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002, 35(Suppl 4):S308-S318.
40. Tolia V, Fitzgerald J, Hassall E, Huang B, Pilmer B, Kane R: Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002, 35(Suppl 4):S300-S307.
41. Gibbons T.E., and Gold B.D. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs 5 (2003) 25-40
42. Rasquin A., Di Lorenzo C., Forbes D., Guiraldes E., Hyams J.S., Staiano A., and Walker L.S. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 130 (2006) 1527-1537